1 |
Carlsson, L. (2006). In vitro and in vivo models for testing arrhythmogenesis in drugs. J. Internal. Medicine. 259, 70-80
DOI
ScienceOn
|
2 |
Cavero, I., Mestre, M., Guillon, J. M. and Crumb, W. (2003). Drugs that prolong QT interval as an unwanted effect: Assessing their likelihood of inducing hazardous cardiac dysrhythmias. Expert Opin. Pharmacother. 1, 947-973
DOI
ScienceOn
|
3 |
Furuhama, K. (2007). Toxicology assessment of fluoroquinolones: A case study. In Nonclinical Drug Safety Assessment: Practical Considerations for Successful Registration(Sietsema, W. K. and Schwen R., Eds.), pp 571-588. FDA news, Falls Church, USA
|
4 |
Hashimoto, K. (2008). Torsades de pointes liability inter-model comparisons: The experience of the QT PRODACT initiative. Pharmacol. Ther. 119, 195-198
DOI
ScienceOn
|
5 |
Pollard, C. E., Valentin, J. P. and Hammond. T. G. (2008). Strategies to reduce the risk of drug-induced QT interval prolongation: a pharmaceutical company perspective. Br. J. Pharmacol. 154, 1538-1543
DOI
ScienceOn
|
6 |
Sugiyama, A. (2008) Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts. Br. J. Pharmacol. 154, 1528-1537
DOI
ScienceOn
|
7 |
Tashibu, H., Miyazaki, H., Aoki, K., Akie, Y. and Yamamoto, K. (2005). QT PRODACT: in vivo QT assay in anesthetized dog for detecting the potential for QT interval prolongation by human pharmaceuticals. J. Pharmacol. Sci. 99, 473-486
DOI
ScienceOn
|
8 |
Belardinelli, L., Shryock, J. C., Wu, L. and Song, Y. (2005). Use of preclinical assays to predict risk of drug-induced torsades de pointes. Heart Rhythm. 2, S16-S22
DOI
ScienceOn
|
9 |
Hanson, L. A., Bass, A. S., Gintant, G., Mittelstadt, S., Rampe, D. and Thomas, K. (2006). ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation. J. Pharmacol. Toxicol. Methods. 54, 116-129
DOI
ScienceOn
|
10 |
Camm, A. J. (2005). Clinical trial design to evaluate the effects of drugs on cardiac repolarization: current state of the art. Heart Rhythm. 2, S23-S29
DOI
ScienceOn
|
11 |
Liu, T., Brown, B. S., Wu, Y., Antzelevitch, C., Kowey, P. R. and Yan, G. X. (2006). Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. Heart Rhythm. 3, 948-956
DOI
ScienceOn
|
12 |
Lu, H. R., Vlaminckx, E., Hermans, A. N., Rohrbacher, J., Van, Ammel. K., Towart. R., Pugsley, M. and Gallacher, D. J. (2008). Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines. Br. J. Pharmacol. 154, 1427-1438
DOI
ScienceOn
|
13 |
Vik, T., Pollard, C. and Sager, P. (2008). Early clinical development: Evaluation of drug-induced torsades de pointes risk. Pharmacol. Ther. 119, 210-214
DOI
ScienceOn
|
14 |
Milberg, P., Eckardt, L., Bruns, H. J., Biertz, J., Ramtin, S., Reinsch, N., Fleischer, D., Kirchhof, P., Fabritz, L., Breithardt, G. and Haverkamp, W. (2002). Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: Fast Phase 3 repolarization prevents early after depolarizations and torsade de pointes J. Pharmacol. Exper. Ther. 303, 218-225
DOI
ScienceOn
|
15 |
Thomsen M. B., Matz, J., Volders P. G. A. and Vos M. A. (2006). Assessing the proarrhythmic potentials of drugs: Current status of models and surrogate parameters of torsades de pointes arrhythmia. Pharmacol. Ther. 112, 150-170
DOI
ScienceOn
|
16 |
Toyoshima, S., Kanno, A., Kitayama, T., Sekiya, K., Nakai, K., Haruna, M., Mino, T., Miyazaki, H., Yano, K. and Yamamoto, K. (2005). QT PRODACT: in vivo QT assay in the conscious dog for assessing the potential for QT interval prolongation by human pharmaceuticals. J. Pharmacol. Sci. 99, 459-471
DOI
ScienceOn
|
17 |
Webster, R., Leishman, D. and Walker, D. (2002). Toward a drug concentration effect relationship for QT prolongation and torsades de pointes. Curr. Opin. Drug Discov. Devel. 5, 116-126
|
18 |
Hoffmann, P. and Warner, B. (2006). Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends. J. Pharmacol. Toxicol. Methods. 53, 87-105
DOI
ScienceOn
|
19 |
Yao, X., Anderson, D. L., Ross, S. A., Lang, D. G., Desai, B. Z., Cooper, D. C., Wheelan, P., McIntyre, M. S., Bergquist, M. L., MacKenzie, K. I., Becherer, J. D. and Hashim, M. A. (2008). Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model. Br. J. Pharmacol. 154, 1446-1456
DOI
ScienceOn
|
20 |
Dumotier, B. M. and Georgieva, A. V. (2007). Preclinical cardio-safety assessment of torsadogenic risk and alternative methods to animal experimentation: the inseparable twins. Cell Biol. Toxicol. 23, 293-302
DOI
|
21 |
Valentin, J. P., Hoffmann, P., De Clerck, F., Hammond, T. G. and Hondeghem, L. (2004). Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs. J. Pharmacol. Toxicol. Methods. 49, 171-181
DOI
ScienceOn
|
22 |
Oros, A., Beekman, J. D. and Vos, M. A. (2008). The canine model with chronic, complete atrio-ventricular block. Pharmacol Ther. 119, 168-178
DOI
ScienceOn
|
23 |
Redfern, W. S., Carlsson, L., Davis, A. S., Lynch, W. G., MacKenzie, I., Palethorpe, S., Siegl, P. K., Strang, I., Sullivan, A. T., Wallis, R., Camm, A. J. and Hammond, TG. (2003). Relationship between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovasc. Res. 58, 32-45
DOI
ScienceOn
|
24 |
Carlsson, L. (2008). The anaesthetised methoxamine-sensitised rabbit model of torsades de pointes Pharmacol. Ther. 119, 160-167
DOI
ScienceOn
|